Navigation Links
Lilly Presents Follow-Up Data on Semagacestat to Assist Future Alzheimer's Disease Research
Date:7/19/2011

nts over this time period. Patients taking 100 mg semagacestat daily (506 patients) worsened by 7.29 points; patients taking 140 mg semagacestat (527 patients) worsened by 7.68 points. Over the seven months after stopping dosing of semagacestat, the differences between placebo- and semagacestat-treated patients were largely unchanged. The adverse effects seen in the IDENTITY trial were similar to those seen during Phase II studies. As disclosed previously and communicated to investigators, patients and regulators earlier in the trials, an increased rate of skin cancer was seen in patients taking semagacestat; this adverse effect was not seen in Phase II studies. The adverse events and laboratory abnormalities seen in the semagacestat-treated subjects resolved shortly after stopping dosing.  

About Semagacestat

Semagacestat was an oral agent designed to reduce the body's production of beta-amyloid, which scientists believe play an important role in causing Alzheimer's disease. Semagacestat is believed to block the activity of gamma secretase, an enzyme that is essential to the body's production of beta-amyloid.

About Eli Lilly and Company

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com.

This press release contains forward-looking statements about compounds currently in clinical development for Alzheimer's disease.  It reflects Lilly's current beliefs; however, as with any such undertaking, there are substantial risks and uncertainties in the process of drug development
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Lilly and Argonne National Laboratory Announce $2 Million Upgrade to Lillys Beamline Capabilities
2. Lilly Donation to Patient Advocate Foundation Expands Services and Access for Patients With Most Common Form of Lung Cancer
3. Lilly CEO Says Biopharmaceuticals Should Be Included in Transatlantic Trade and Economic Discussions
4. Lilly CEO Calls for Improved Dialogue in Germany Between Industry and the Government and Health Care System
5. Lilly Quality Leader Walsh Appointed to Companys Executive Committee
6. Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations
7. Lilly Announces New Investment to Further Boost Its Biotechnology Capabilities
8. Lilly Declares Third-Quarter 2011 Dividend
9. Lilly for Better Health™ Launches Enhanced Multi-Channel Patient Education Platform
10. Synthes and Lilly Sign Development and Collaboration Agreement
11. U.S. District Court Rules in Favor of Lilly in Amylin Litigation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... , Aug. 27, 2015 The nation,s newest Actos ... Las Vegas courtroom.  Attorneys representing two ... men suffered severe effects, including death, after using the diabetes ... what they as a company knew, that their drug Actos ... Robert Eglet .  "In order to hold Takeda responsible it ...
(Date:8/27/2015)... , Aug. 27, 2015  BioElectronics Corporation (OTC Pink: BIEL), ... that three abstracts featuring the use of ActiPatch®, its ... 9 th Congress of the European Pain Federation ... September 2015. The Company will also be exhibiting ... Gianluca Bagnato , department clinical and experimental rheumatology ...
(Date:8/27/2015)... 27, 2015  PinnacleHealth CardioVascular Institute enrolled the first patient ... the United States in a trial assessing ... for blockages in the main artery of the leg. The ... potentially less risk for stent fracture or re-narrowing after the ... multicenter clinical trial of the BioMimics 3D Stent System and ...
Breaking Medicine Technology:2 Billion Dollar Verdict Sought In Actos Trial 2BioElectronics Selected to Present its Pain Research and Devices at the European Pain Federation Conference 2First Pennsylvania Patient Treated in Landmark Vascular Study 2
(Date:8/28/2015)... , ... August 28, 2015 , ... The newest therapy ... be available for general use any time soon, according to educational website Surviving Mesothelioma. ... therapy that received orphan drug designation for mesothelioma last week from the FDA, will ...
(Date:8/28/2015)... Indianapolis, IN (PRWEB) , ... August 28, 2015 ... ... employee benefits advisory organization, is pleased to welcome TJS Insurance Group as its ... to employees and clients guides them and keeps them focused on their goals. ...
(Date:8/28/2015)... ... ... External Counterpulsation, also known as ECP or EECP, is a proven treatment ... ECP) machines with a full clinic licence to help people prevent and reverse heart ... prevent and reverse heart disease through its evidence-based integrative approach to heart ...
(Date:8/28/2015)... ... August 28, 2015 , ... Yisrayl Hawkins, Pastor and ... and pleads for swift actions to be taken in order to ease the ... , Yisrayl says scientists have yet to understand fully the real cause of global ...
(Date:8/28/2015)... ... August 28, 2015 , ... Inc. magazine today ranked PREVENT Life ... of the nation’s fastest-growing private companies. The list was unveiled online at Inc.com and ... over the last three years, PREVENT ranks higher on the list than any other ...
Breaking Medicine News(10 mins):Health News:Surviving Mesothelioma Puts New Orphan Drug into Perspective in New Article 2Health News:TJS Insurance Group Is Latest Partner Firm To Join United Benefit Advisors 2Health News:TJS Insurance Group Is Latest Partner Firm To Join United Benefit Advisors 3Health News:Buy New External Counterpulsation (EECP or ECP) With Heart Fit Clinic 2Health News:Wake Up and Smell the Sick Atmosphere Says Yisrayl Hawkins in New Article This Week 2Health News:PREVENT Life Safety Ranks No. 3660 on the 2015 Inc. 5000 With Three-Year Sales Growth of 85% 2
... may be beneficial in preventing severe long-term disability in multiple ... treatment for the chronic progressive phase of MS, when serious ... Children's Hospital Boston study appearing in the Journal of Neuroscience, ... type of vitamin B3 known as nicotinamide cut the risk ...
... help reduce Alzheimer's disease, says a study on mice, but ... findings apply to people.// ,Jun Wang and other researchers ... mice with genes that order the production of amyloid-beta protein, ... reported the online edition of science magazine WebMD. ...
... the basic purpose of a sunscreen lotion as well as ... well on the threshold of a discovery; Scientists have found ... the fair skin people from tanning as well as guard ... David E. Fisher, director of the Melanoma Program at the ...
... 80% of people suffering from severe chronic lung disease ... of it.// ,Chronic Bronchitis and Emphysema constitute the ... lung tissue by smoking can lead to the development ... ,Professor Robert West, director of tobacco studies at Cancer ...
... particularly those with high levels of low-density lipoprotein ... according to a study in the September 20 ... specific class of lipoprotein particles found in human ... according to background information in the article. Studies ...
... kidney cancer has been rising over the last two decades, ... Center shows// that this increase is driven largely by the ... the rising incidence has been paralleled by greater use of ... fewer people dying. ,“With increased early detection and treatment ...
Cached Medicine News:Health News:Vitamin Shots to Combat MS Pain 2Health News:80% of lung disease remains ‘undiagnosed’. 2Health News:High Levels of Lipoprotein(a) in Women is Associated With Cardiovascular Risk 2Health News:More Kidney Cancer Is Detected and Treated Early, Yet Death Rate Rises 2Health News:More Kidney Cancer Is Detected and Treated Early, Yet Death Rate Rises 3
The Onyx® 9500 worlds first self-contained digital fingertip pulse oximeter incorporates the electronics and the sensor into one unit....
Ergonomically designed, the Invacare Printing Pulse Oximeter provides fast, reliable spot-check information and documentation of SpO2 and pulse rate. It is ideal for all patients from neonate to adul...
... The Invacare Digital Pulse ... and pulse strength. It is ... measurements on challenging patients. The ... other artifacts, informs the operator ...
Rad-9™...
Medicine Products: